感染HIV女性的HPV血清学:型特异性血清阳性率、血清转换与宫颈再感染风险
任意HPV血清阳性率93.2%,219名基线宫颈HPV-DNA阳性且同型血清阴性者中51人(23.3%)发生型特异性血清转换。基线HPV18、35、58血清阳性者宫颈HPV-DNA获得风险较低。
要点
- 感染HIV女性任意HPV血清阳性率达93.2%,二价、四价、九价疫苗覆盖型别同时血清阳性率分别为21.4%、10.9%、2.8%。
- 219名基线宫颈HPV-DNA阳性且同型血清阴性者中,51人(23.3%)在16个月时发生型特异性血清转换。
- 近期使用ART(≤2年 vs 未治疗)与血清转换风险升高相关(aOR=2.39;95%CI 1.02-5.62)。
核心结论
- 感染HIV女性对基线HPV-DNA存在血清转换证据,且依赖于CD4+计数和ART。
- 基线HPV血清阳性对部分HPV型别提供有限保护。
研究设计与样本
- 前瞻性研究,纳入南非约翰内斯堡604名25-50岁感染HIV女性。
主要发现
- 任意HPV血清阳性率为93.2%;二价(HPV16/18)、四价(HPV6/11/16/18)、九价(HPV6/11/16/18/31/33/45/52/58)疫苗覆盖型别同时血清阳性率分别为21.4%、10.9%、2.8%。
- 219名基线宫颈HPV-DNA阳性、同型血清阴性且无高级别宫颈上皮内瘤变者中,51人(23.3%)在终点发生型特异性血清转换。
- 近期使用ART(≤2年 vs 未治疗)者型特异性血清转换风险更高(aOR=2.39;95%CI 1.02-5.62)。
- 终点CD4+≤350 vs >350 cells/mm3者型特异性血清转换风险更低(aOR=0.51;95%CI 0.24-1.07)。
- 基线HPV18、35、58血清阳性者宫颈HPV-DNA获得风险较低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) serodynamics following infection has never been evaluated prospectively among women living with HIV (WLHIV). We determined HPV seroprevalence, seroconversion, and cervical HPV-DNA acquisition among WLHIV. METHODS: Prospective study of 604 WLHIV in Johannesburg, South Africa aged 25-50 years. At baseline and 16 months (endline), HPV type-specific antibodies (HPV6/11/16/18/31/33/35/39/45/52/56/58/59/68/73) were measured using HPV-pseudovirions and cervical HPV-DNA genotypes using INNO-LiPA. RESULTS: Seroprevalence of any-HPV was 93.2% and simultaneous seropositivity for HPV types of the bivalent (HPV16/18), quadrivalent (HPV6/11/16/18), and nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccines were 21.4%, 10.9%, and 2.8%. Among 219 women with cervical HPV-DNA, same-type seronegative and without high-grade cervical intraepithelial neoplasia at baseline, 51 (23.3%) had type-specific seroconversion at endline. Risk of type-specific seroconversion was higher among recent antiretroviral therapy users (ART ≤2 years vs ART naive: adjusted OR [aOR] = 2.39; 95% CI, 1.02-5.62), and lower among women with low CD4+ at endline (≤350 vs >350 cells/mm3: aOR = 0.51; 95% CI, 0.24-1.07). Risk of cervical HPV-DNA acquisition was lower in women seropositive for HPV18, 35, and 58 at baseline. CONCLUSION: WLHIV have evidence of seroconversion in response to baseline HPV-DNA, dependent on CD4+ count and ART. Baseline HPV seropositivity confers limited protection against some HPV types.
引用
- Kelly H, Faust H, Chikandiwa A, et al. Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection. J Infect Dis. 2018. PMID: 29850832. doi:10.1093/infdis/jiy252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。